NCT05315999 2025-03-19
ProTreat
University Hospital Freiburg
Phase 2 Completed
Clinical Trials
24 trialsNCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT02991456 2023-07-11
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Duke University
Phase 2 Completed
NCT03948477 2022-05-25
PantoCIN
University of Auckland, New Zealand
Phase 2 Completed
NCT03572829 2020-07-15
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
ChineseAMS
Phase 2 Completed
NCT03862144 2019-03-05
GIM15-NEPA
Consorzio Oncotech
Phase 2 Completed
NCT01534637 2018-08-15
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT01450826 2018-06-26
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Duke University
Phase 2 Completed
NCT00381862 2017-06-12
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00064272 2016-10-21
IRB 2003-551
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02787707 2016-06-03
Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting
Mashhad University of Medical Sciences
Phase 2 Completed
NCT01736917 2016-05-25
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Completed
NCT00003817 2015-10-15
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
University of Rochester
Phase 2 Completed
NCT00954941 2015-06-25
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00450853 2015-01-27
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed
NCT01387841 2013-07-24
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
Bharath Charitable Cancer Hospital and Institute
Phase 2 Completed
NCT01012336 2012-10-10
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Samsung Medical Center
Phase 2 Completed
NCT01031498 2012-08-07
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00212602 2012-06-14
ONO-7436 Phase II Study in Japan
Ono Pharmaceutical Co. Ltd
Phase 2 Completed
NCT00004895 2012-06-06
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Northwestern University
Phase 2 Completed
NCT00250744 2011-09-27
Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00169572 2010-05-10
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
GlaxoSmithKline
Phase 2 Completed
NCT01018758 2009-11-25
NHLPal
Gruppo Italiano Studio Linfomi
Phase 2 Completed
NCT00666783 2008-04-25
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
Xijing Hospital
Phase 2 Completed